Drawing for VALENCE LABS

USPTO serial 98137246

VALENCE LABS

Reviewed by CopyMark Law Group

Status 819
Filing date
Status date
Registration date
—
Examiner
MIZELLE HOWARD, DEZMONA JULYE
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VALENCE LABS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David Johnson

David Johnson WORKMAN NYDEGGER60 E SOUTH TEMPLESUITE 1000SALT LAKE CITY, UT 84111

Goods and services

ClassDescriptionStatusFirst use
042Pharmaceutical research and development services; Scientific research and development of pharmaceutical preparations; Pharmaceutical research services, namely, developing new uses for pharmaceutical compounds through the use of computer models, animal models, and controlled environments; Contract research services in support of scientific research and development of pharmaceutical preparations; Technical consultancy and services in relation to technical research in the field of pharmaceuticals; Consultancy in relation to scientific research in the field of pharmaceuticals; Providing medical research and scientific research information in the field of medicine and pharmaceuticals; Drug discovery services; Drug use discovery services; scientific and technological services, namely, medical laboratories, scientific research and design for others in the field of pharmaceuticals, conducting and evaluating clinical trials; software as a service (SaaS) featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; Providing an online searchable database in the fields of pharmaceutical research and development, scientific research and development of pharmaceutical preparations, developing new uses for pharmaceutical compounds, technical research in the field of pharmaceuticals, drug use, drug discovery, and biology understanding; Providing an online database in the fields of pharmaceutical research and development, scientific research and development of pharmaceutical preparations, developing new uses for pharmaceutical compounds, technical research in the field of pharmaceuticals, drug use, drug discovery, and biology understandingACTIVEJul 26, 2023

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 26, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 26, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Oct 7, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Sep 18, 2026IUAFUSE AMENDMENT FILED—
Sep 18, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jun 27, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 26, 2026EX1GSOU EXTENSION 1 GRANTED—
Jun 26, 2026EXT1SOU EXTENSION 1 FILED—
Jun 26, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 6, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 11, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 11, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 5, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 15, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 8, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 3, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 3, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 3, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jan 13, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jul 2, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jul 2, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Jul 2, 2024CNSLSUSPENSION LETTER WRITTEN—
Jul 2, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 2, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 2, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 18, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 18, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 17, 2024DOCKASSIGNED TO EXAMINER—
Sep 15, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 21, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance